Fig. 5

Alpelisib improves patients with PIK3CA or TEK-related capillary venous malformations. a Representative Hematoxylin and eosin (H&E) staining and b Immunofluorescence of P-AKT^Thr308 and P-S6RP in skin biopsies performed in controls and in patients with PIK3CA-related capillary venous malformation. Scale bar: 10 μm. c Immunofluorescence quantification (n = 6 controls and 6 patients). AU Arbitrary units. d Representative photographs of the morphological changes observed in patients with PIK3CA-related capillary venous malformations receiving alpelisib for 6 months. e Representative photographs of the morphological changes observed in patients with TEK-related capillary venous malformations receiving alpelisib for 6 months. f Transversal (upper panel) and coronal (lower panel) T2-weighted fat saturated MRI sequence of patient 1 and 5 before and after alpelisib introduction. In red, segmentation in 2D (left panel) and 3D (right panel). g Percentage change of the volume of the preselected lesion in patients with PIK3CA-related capillary venous malformations (left panel) and TEK-related capillary venous malformations (right panel)